과제정보
This research received funding from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, Information and Communication Technologies & Future Planning (2020R1A2C1003886).
참고문헌
- Louis DN, Perry A, Reifenberger G, von Deimling A, FigarellaBranger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803-820 https://doi.org/10.1007/s00401-016-1545-1
- Hu LS, Ning S, Eschbacher JM, Baxter LC, Gaw N, Ranjbar S, et al. Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro Oncol 2017;19:128-137 https://doi.org/10.1093/neuonc/now135
- Park YW, Han K, Ahn SS, Bae S, Choi YS, Chang JH, et al. Prediction of IDH1-mutation and 1p/19q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas. AJNR Am J Neuroradiol 2018;39:37-42 https://doi.org/10.3174/ajnr.A5421
- Kratochwil C, Combs SE, Leotta K, Afshar-Oromieh A, Rieken S, Debus J, et al. Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors. Neuro Oncol 2014;16:434-440 https://doi.org/10.1093/neuonc/not199
- Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, et al. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro Oncol 2014;16:603-609 https://doi.org/10.1093/neuonc/not166
- Kim HS, Goh MJ, Kim N, Choi CG, Kim SJ, Kim JH. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility. Radiology 2014;273:831-843 https://doi.org/10.1148/radiol.14132868
- Kong DS, Kim ST, Kim EH, Lim DH, Kim WS, Suh YL, et al. Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011;32:382-387 https://doi.org/10.3174/ajnr.A2286
- Louis DN, Ellison DW, Brat DJ, Aldape K, Capper D, Hawkins C, et al. cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates. Brain Pathol 2019;29:469-472 https://doi.org/10.1111/bpa.12732
- Batchala PP, Muttikkal TJE, Donahue JH, Patrie JT, Schiff D, Fadul CE, et al. Neuroimaging-based classification algorithm for predicting 1p/19q-codeletion status in IDH-mutant lower grade gliomas. AJNR Am J Neuroradiol 2019;40:426-432 https://doi.org/10.3174/ajnr.A5957
- Lee MK, Park JE, Jo Y, Park SY, Kim SJ, Kim HS. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign. Eur Radiol 2020;30:844-854 https://doi.org/10.1007/s00330-019-06395-2
- Patel SH, Poisson LM, Brat DJ, Zhou Y, Cooper L, Snuderl M, et al. T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. Clin Cancer Res 2017;23:6078-6085 https://doi.org/10.1158/1078-0432.CCR-17-0560
- Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481-2498 https://doi.org/10.1056/NEJMoa1402121
- Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ. Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis. Eur Radiol 2019;29:745-758 https://doi.org/10.1007/s00330-018-5608-7
- Park YW, Han K, Ahn SS, Choi YS, Chang JH, Kim SH, et al. Whole-tumor histogram and texture analyses of DTI for evaluation of IDH1-mutation and 1p/19q-codeletion status in World Health Organization Grade II gliomas. AJNR Am J Neuroradiol 2018;39:693-698 https://doi.org/10.3174/ajnr.A5569
- Zhou H, Vallieres M, Bai HX, Su C, Tang H, Oldridge D, et al. MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro Oncol 2017;19:862-870 https://doi.org/10.1093/neuonc/now256
- Chang K, Bai HX, Zhou H, Su C, Bi WL, Agbodza E, et al. Residual convolutional neural network for the determination of IDH status in low-and high-grade gliomas from MR imaging. Clin Cancer Res 2018;24:1073-1081 https://doi.org/10.1158/1078-0432.CCR-17-2236
- Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012;18:624-629 https://doi.org/10.1038/nm.2682
- Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, et al. Static and dynamic 18F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. Eur J Nucl Med Mol Imaging 2018;45:443-451 https://doi.org/10.1007/s00259-017-3846-6
- Lohmann P, Lerche C, Bauer EK, Steger J, Stoffels G, Blau T, et al. Predicting IDH genotype in gliomas using FET PET radiomics. Sci Rep 2018;8:13328
- Park YW, Ahn SS, Park CJ, Han K, Kim EH, Kang SG, et al. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas. Eur Radiol 2020;30:6475-6484 https://doi.org/10.1007/s00330-020-07090-3
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996 https://doi.org/10.1056/NEJMoa043330
- Lee S, Choi SH, Ryoo I, Yoon TJ, Kim TM, Lee SH, et al. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neurooncol 2015;121:141-150 https://doi.org/10.1007/s11060-014-1614-z
- Price SJ, Allinson K, Liu H, Boonzaier NR, Yan JL, Lupson VC, et al. Less invasive phenotype found in isocitrate dehydrogenase-mutated glioblastomas than in isocitrate dehydrogenase wild-type glioblastomas: a diffusion-tensor imaging study. Radiology 2017;283:215-221 https://doi.org/10.1148/radiol.2016152679
- Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003 https://doi.org/10.1056/NEJMoa043331
- Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ. Clinically relevant imaging features for MGMT promoter methylation in multiple glioblastoma studies: a systematic review and meta-analysis. AJNR Am J Neuroradiol 2018;39:1439-1445
- Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol 2016;26:569-580 https://doi.org/10.1111/bpa.12336
- Aboian MS, Solomon DA, Felton E, Mabray MC, Villanueva-Meyer JE, Mueller S, et al. Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation. AJNR Am J Neuroradiol 2017;38:795-800 https://doi.org/10.3174/ajnr.A5076
- Jung JS, Choi YS, Ahn SS, Yi S, Kim SH, Lee SK. Differentiation between spinal cord diffuse midline glioma with histone H3 K27M mutation and wild type: comparative magnetic resonance imaging. Neuroradiology 2019;61:313-322 https://doi.org/10.1007/s00234-019-02154-8
- Koeller KK, Rushing EJ. From the archives of the AFIP: pilocytic astrocytoma: radiologic-pathologic correlation. Radiographics 2004;24:1693-1708 https://doi.org/10.1148/rg.246045146
- Alkonyi B, Nowak J, Gnekow AK, Pietsch T, Warmuth-Metz M. Differential imaging characteristics and dissemination potential of pilomyxoid astrocytomas versus pilocytic astrocytomas. Neuroradiology 2015;57:625-638 https://doi.org/10.1007/s00234-015-1498-4
- Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014;14:455-467 https://doi.org/10.1038/nrc3760
- Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121:397-405 https://doi.org/10.1007/s00401-011-0802-6
- Koeller KK, Henry JM. From the archives of the AFIP: superficial gliomas: radiologic-pathologic correlation. Armed Forces Institute of Pathology. Radiographics 2001;21:1533-1556 https://doi.org/10.1148/radiographics.21.6.g01nv051533
- Hsu C, Kwan G, Lau Q, Bhuta S. Rosette-forming glioneuronal tumour: imaging features, histopathological correlation and a comprehensive review of literature. Br J Neurosurg 2012;26:668-673 https://doi.org/10.3109/02688697.2012.655808
- Mack SC, Taylor MD. Put away your microscopes: the ependymoma molecular era has begun. Curr Opin Oncol 2017;29:443-447 https://doi.org/10.1097/MOP.0000000000000513
- Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y, et al. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 2014;506:451-455 https://doi.org/10.1038/nature13109
- Nowak J, Junger ST, Huflage H, Seidel C, Hohm A, Vandergrift LA, et al. MRI phenotype of RELA-fused pediatric supratentorial ependymoma. Clin Neuroradiol 2019;29:595-604 https://doi.org/10.1007/s00062-018-0704-2
- Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 2017;31:737-754.e6 https://doi.org/10.1016/j.ccell.2017.05.005
- Perreault S, Ramaswamy V, Achrol AS, Chao K, Liu TT, Shih D, et al. MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol 2014;35:1263-1269 https://doi.org/10.3174/ajnr.A3990
- Iv M, Zhou M, Shpanskaya K, Perreault S, Wang Z, Tranvinh E, et al. MR imaging-based radiomic signatures of distinct molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol 2019;40:154-161 https://doi.org/10.3174/ajnr.A5899
- Raybaud C, Ramaswamy V, Taylor MD, Laughlin S. Posterior fossa tumors in children: developmental anatomy and diagnostic imaging. Childs Nerv Syst 2015;31:1661-1676 https://doi.org/10.1007/s00381-015-2834-z
- AlRayahi J, Zapotocky M, Ramaswamy V, Hanagandi P, Branson H, Mubarak W, et al. Pediatric brain tumor genetics: what radiologists need to know. Radiographics 2018;38:2102-2122 https://doi.org/10.1148/rg.2018180109
- Dangouloff-Ros V, Tauziede-Espariat A, Roux CJ, Levy R, Grevent D, Brunelle F, et al. CT and multimodal MR imaging features of embryonal tumors with multilayered rosettes in children. AJNR Am J Neuroradiol 2019;40:732-736
- Shih RY, Koeller KK. Embryonal tumors of the central nervous system: from the radiologic pathology archives. Radiographics 2018;38:525-541 https://doi.org/10.1148/rg.2018170182
- Weon YC, Kim EY, Kim HJ, Byun HS, Park K, Kim JH. Intracranial solitary fibrous tumors: imaging findings in 6 consecutive patients. AJNR Am J Neuroradiol 2007;28:1466-1469 https://doi.org/10.3174/ajnr.A0609
- Smith JS, Cha S, Mayo MC, McDermott MW, Parsa AT, Chang SM, et al. Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg 2005;103:428-438 https://doi.org/10.3171/jns.2005.103.3.0428
- Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-1972 https://doi.org/10.1200/JCO.2009.26.3541
- Yun TJ, Park CK, Kim TM, Lee SH, Kim JH, Sohn CH, et al. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. Radiology 2015;274:830-840 https://doi.org/10.1148/radiol.14132632
- Vrabec M, Van Cauter S, Himmelreich U, Van Gool SW, Sunaert S, De Vleeschouwer S, et al. MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study. Neuroradiology 2011;53:721-731 https://doi.org/10.1007/s00234-010-0802-6
- Kim JY, Park JE, Jo Y, Shim WH, Nam SJ, Kim JH, et al. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients. Neuro Oncol 2019;21:404-414 https://doi.org/10.1093/neuonc/noy133
- Park YW, Ahn SS, Kim EH, Kang SG, Chang JH, Kim SH, et al. Differentiation of recurrent diffuse glioma from treatment-induced change using amide proton transfer imaging: incremental value to diffusion and perfusion parameters. Neuroradiology 2021;63:363-372 https://doi.org/10.1007/s00234-020-02542-5
- van Dijken BRJ, van Laar PJ, Holtman GA, van der Hoorn A. Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis. Eur Radiol 2017;27:4129-4144 https://doi.org/10.1007/s00330-017-4789-9
- Galldiks N, Lohmann P, Albert NL, Tonn JC, Langen KJ. Current status of PET imaging in neuro-oncology. Neurooncol Adv 2019;1:vdz010
- Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR Am J Neuroradiol 2013;34:944-950, S1-S11
- Rieger J, Bahr O, Muller K, Franz K, Steinbach J, Hattingen E. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 2010;99:49-56 https://doi.org/10.1007/s11060-009-0098-8
- Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, et al. Progressing bevacizumab-induced diffusion restriction is associated with coagulative necrosis surrounded by viable tumor and decreased overall survival in patients with recurrent glioblastoma. AJNR Am J Neuroradiol 2016;37:2201-2208 https://doi.org/10.3174/ajnr.A4898
- Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 2018;15:422-442 https://doi.org/10.1038/s41571-018-0003-5
- Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 2016;375:2561-2569 https://doi.org/10.1056/NEJMoa1610497
- Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 2015;16:e534-e542 https://doi.org/10.1016/S1470-2045(15)00088-1
- Mehta AM, Sonabend AM, Bruce JN. Convection-enhanced delivery. Neurotherapeutics 2017;14:358-371 https://doi.org/10.1007/s13311-017-0520-4
- Sonabend AM, Stuart RM, Yun J, Yanagihara T, Mohajed H, Dashnaw S, et al. Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro Oncol 2011;13:886-893 https://doi.org/10.1093/neuonc/nor051
- Mardor Y, Rahav O, Zauberman Y, Lidar Z, Ocherashvilli A, Daniels D, et al. Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res 2005;65:6858-6863 https://doi.org/10.1158/0008-5472.CAN-05-0161
- Medvid R, Ruiz A, Komotar RJ, Jagid JR, Ivan ME, Quencer RM, et al. Current applications of MRI-guided laser interstitial thermal therapy in the treatment of brain neoplasms and epilepsy: a radiologic and neurosurgical overview. AJNR Am J Neuroradiol 2015;36:1998-2006 https://doi.org/10.3174/ajnr.A4362
- Schwabe B, Kahn T, Harth T, Ulrich F, Schwarzmaier HJ. Laser-induced thermal lesions in the human brain: short-and long-term appearance on MRI. J Comput Assist Tomogr 1997;21:818-825 https://doi.org/10.1097/00004728-199709000-00031